Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DNL 126

Drug Profile

DNL 126

Alternative Names: DNL-126; ETV:N-sulphoglucosamine sulphohydrolase; ETV:SGSH; Recombinant sulphoglucosamine sulphohydrolase - Denali Therapeutics

Latest Information Update: 11 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Denali Therapeutics Inc
  • Class Hydrolases; Recombinant fusion proteins
  • Mechanism of Action N-sulfoglucosamine sulfohydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes
  • Available For Licensing Yes - Mucopolysaccharidosis III

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 06 Feb 2026 Denali expects a BLA submission for DNL 126 for MPS IIIA in 2027
  • 06 Feb 2026 Denali expects approval for DNL 126 for MPS IIIA in 2027
  • 05 Feb 2026 Efficacy, pharmacodynamics and adverse events data from phase I/II trial in Mucopolysaccharidosis III A released by Denali Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top